JP2025514763A5 - - Google Patents
Info
- Publication number
- JP2025514763A5 JP2025514763A5 JP2024561852A JP2024561852A JP2025514763A5 JP 2025514763 A5 JP2025514763 A5 JP 2025514763A5 JP 2024561852 A JP2024561852 A JP 2024561852A JP 2024561852 A JP2024561852 A JP 2024561852A JP 2025514763 A5 JP2025514763 A5 JP 2025514763A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- multispecific antibody
- amino acid
- antibody according
- constant domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333293P | 2022-04-21 | 2022-04-21 | |
| US63/333,293 | 2022-04-21 | ||
| PCT/US2023/066036 WO2023205753A1 (en) | 2022-04-21 | 2023-04-20 | Chimeric heavy chain constant domains with reduced binding to fc gamma receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025514763A JP2025514763A (ja) | 2025-05-09 |
| JP2025514763A5 true JP2025514763A5 (enExample) | 2026-04-28 |
Family
ID=86425985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024561852A Pending JP2025514763A (ja) | 2022-04-21 | 2023-04-20 | Ｆｃガンマ受容体への結合が低減されたキメラ重鎖定常ドメイン及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250109207A1 (enExample) |
| EP (1) | EP4511398A1 (enExample) |
| JP (1) | JP2025514763A (enExample) |
| KR (1) | KR20250007564A (enExample) |
| CN (2) | CN117597365A (enExample) |
| AU (1) | AU2023255761A1 (enExample) |
| CA (1) | CA3249454A1 (enExample) |
| WO (1) | WO2023205753A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4638729A1 (en) | 2022-12-23 | 2025-10-29 | Regeneron Pharmaceuticals, Inc. | Ace2 fusion proteins and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| ES2102007T3 (es) | 1992-01-23 | 1997-07-16 | Merck Patent Gmbh | Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| GB9824437D0 (en) | 1998-11-06 | 1999-01-06 | Ylo Herttuala Seppo | Gene therapy |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| WO2005049094A1 (en) | 2003-11-13 | 2005-06-02 | Advantagene, Inc. | A mixed complementary viral vector for gene therapy |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| LT2975051T (lt) * | 2009-06-26 | 2021-07-12 | Regeneron Pharmaceuticals, Inc. | Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| CA2822366A1 (en) * | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| MX385344B (es) | 2012-11-28 | 2025-03-18 | Zymeworks Bc Inc | Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos. |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| ES2821753T3 (es) | 2013-03-15 | 2021-04-27 | Lilly Co Eli | Procedimientos de producción de Fab y de anticuerpos biespecíficos |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| CA3157075A1 (en) | 2019-11-05 | 2021-05-14 | Regeneron Pharmaceuticals, Inc. | N-terminal scfv multispecific binding molecules |
| EP4093430A4 (en) * | 2020-01-21 | 2024-01-24 | Tavotek Biotherapeutics (Hong Kong) Limited | AGENTS THAT INTERFERE WITH IL-1 RECEPTOR SIGNALING? |
-
2022
- 2022-05-03 CN CN202280047414.2A patent/CN117597365A/zh active Pending
-
2023
- 2023-04-20 CN CN202380048565.4A patent/CN119546637A/zh active Pending
- 2023-04-20 US US18/857,898 patent/US20250109207A1/en active Pending
- 2023-04-20 JP JP2024561852A patent/JP2025514763A/ja active Pending
- 2023-04-20 CA CA3249454A patent/CA3249454A1/en active Pending
- 2023-04-20 EP EP23725348.9A patent/EP4511398A1/en active Pending
- 2023-04-20 KR KR1020247038245A patent/KR20250007564A/ko active Pending
- 2023-04-20 WO PCT/US2023/066036 patent/WO2023205753A1/en not_active Ceased
- 2023-04-20 AU AU2023255761A patent/AU2023255761A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP7788113B2 (ja) | Ｃｈ３ドメインに基づくヘテロダイマー分子、その調製方法及び用途 | |
| US12522654B2 (en) | Engineered heterodimeric proteins | |
| JP2022504550A5 (enExample) | ||
| Klein et al. | Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies | |
| CA3065868C (en) | Novel hetero-dimeric multi-specific antibody format | |
| KR101851380B1 (ko) | 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍 | |
| JP2015522525A5 (enExample) | ||
| JP2018537966A5 (enExample) | ||
| Asano et al. | Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody | |
| CN113490690A (zh) | 异源二聚体融合蛋白 | |
| Spasevska | An outlook on bispecific antibodies: Methods of production and therapeutic benefits | |
| JP2024507693A5 (enExample) | ||
| JP2022518282A5 (enExample) | ||
| JPWO2022102768A5 (enExample) | ||
| JP2026064000A (ja) | 抗原結合分子 | |
| RU2025130619A (ru) | Биспецифические агонистические антитела к рецептору i типа, подобному рецептору активина а (alk1) | |
| RU2024139941A (ru) | Способы очистки полиспецифических антител | |
| Fayadat-Dilman | Novel Technologies for Generation of Bispecific Constructs | |
| RU2024126644A (ru) | Двухвалентное биспецифическое антитело и способ его получения | |
| NZ793791B2 (en) | Multispecific heavy chain antibodies with modified heavy chain constant regions | |
| Jin et al. | The design and engineering of IgG-like bispecific antibodies | |
| AR122458A1 (es) | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas | |
| EA041608B1 (ru) | Гетеродимерный полиспецифичный формат антител | |
| Florin et al. | 4.2 Manufacturing of Complex Biotherapeutic Protein Products: Medical Need and Rational for Monoclonal Antibody Mixtures, Multispecific Formats, and Fc-fusion Proteins |